Construction of a novel protein vaccine against monkeypox virus and evaluation of its immune response
Objective To construct monkeypoxvirus(MPXV)and vaccinia virus(VACV)protein vaccines and evaluate antibody activity induced by them.Methods MPXV-A29-Fc and VACV-A27-Fc protein vac-cines were constructed by fusion protein expression technology.The binding capacity of proteins was de-tected by ELISA and WB in vitro.Titer of antibody elicited by the protein was detected by immunizing fe-male BALB/c mice in vivo.Results Both MPXV-A29-Fc and VACV-A27-Fc proteins could bind to A29 mAb.MPXV-A29 and VACV-A27 proteins can be cross-recognized by the serum of mice immunized with MPXV-A29-Fc and VACV-A27-Fc proteins.3-dose vaccination could induce stronger cross-immune re-sponses.After 3 doses of MPXV-A29-Fc or VACV-A27-Fc in mice,the binding capacity of IgG antibody in the low-dose group was similar to that in the high-dose group at different serum dilutions,which could achieve the effective vaccination of the high-dose group.Conclusions In this study,novel vaccines MPXV-A29-Fc and VACV-A27-Fc,which can induce specific antibody response and cross-antibody response in mice,and they are successfully prepared.It provides a new idea and candidate for the design of MPXV vaccine.
monkeypox virus(MPXV)recombinant protein vaccinebinding activitycross reactivity
万方数据
维普
